Catalent New Product Introduction Process
Catalent, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, employs an active New Product Introduction (NPI) programme, which has seen the global introduction of nearly a hundred new consumer health and Rx products in the last year.
Catalent New Product Introduction Process
Catalent, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, employs an active New Product Introduction (NPI) programme, which has seen the global introduction of nearly a hundred new consumer health and Rx products in the last year. Catalent has an active NPI pipeline of several hundred products and the number of NPIs completed has grown significantly year-on-year.
Catalent employs rigorous systems to drive and deliver robust, “right first time” development and technical transfer into reliable manufacture and supply.
www.catalent.com[email protected]
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
